Your browser doesn't support javascript.
loading
Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Holzner, Matthew L; Florman, Sander; Schwartz, Myron E; Tabrizian, Parissa.
Afiliación
  • Holzner ML; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.holzner@mountsinai.org.
  • Florman S; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Schwartz ME; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tabrizian P; Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
HPB (Oxford) ; 24(4): 470-477, 2022 04.
Article en En | MEDLINE | ID: mdl-34544629
BACKGROUND: Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is the second-leading cause of liver transplantation (LT) performed for HCC. Despite this, little is known about the clinical characteristics and outcomes of NASH-HCC. METHODS: Patients undergoing LT for HCC from 2001 to 2017 at a single center were reviewed. Outcomes of NASH-HCC (n = 51) were compared to other etiologies of HCC including hepatitis C (HCV) hepatitis B (HBV), and alcoholic liver disease (ALD). Outcomes of NASH-HCC were also compared to HCV in the direct-acting antiviral (DAA) era (2014-2017). RESULTS: The frequency of NASH-HCC as the primary indication for LT in patients with HCC increased significantly during the study period from 4.4% (2001-2008) to 15.6% in 2017. NASH-HCC patients were significantly older (median age 65 vs. 60; P < 0.001) with significantly lower alpha-fetoprotein levels (7.5 vs. 26.5, P < 0.001) compared to other etiologies. The 1-, 3-, and 5-year overall survival of NASH-HCC was 92%, 86%, and 80%. Overall survival of NASH-HCC was not significantly different compared to HCV, HBV, or ALD. Compared to HCV-HCC in the DAA era (n = 99), NASH-HCC had comparable post-LT survival (3-year survival 87% vs. 86%, P = 0.870). CONCLUSION: In this large single-center experience of NASH-HCC, we demonstrate favorable outcomes of NASH-HCC following LT comparable to other common etiologies of HCC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Hepatitis C / Carcinoma Hepatocelular / Hepatitis C Crónica / Enfermedad del Hígado Graso no Alcohólico / Hepatopatías Alcohólicas / Neoplasias Hepáticas Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: HPB (Oxford) Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Hepatitis C / Carcinoma Hepatocelular / Hepatitis C Crónica / Enfermedad del Hígado Graso no Alcohólico / Hepatopatías Alcohólicas / Neoplasias Hepáticas Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: HPB (Oxford) Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido